menu
    • menu
    [{"orgOrder":0,"company":"Pierre Fabre","sponsor":"Terran Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"FRANCE","productType":"Small molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Idazoxan","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Pierre Fabre","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"","sponsorNew":"Pierre Fabre \/ Terran Biosciences","highestDevelopmentStatusID":"8","companyTruncated":"Pierre Fabre \/ Terran Biosciences"}]

    Find Clinical Drug Pipeline Developments & Deals for Idazoxan

    Menu

    Idazoxan

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
    filter

    Year

    filter

    DEALS // DEV.

    filter

    Country

    filter
    Sponsor
    filter

    Therapeutic Area

    filter

    Study Phase

    filter

    Deal Type

    filter

    Product Type

    filter

    Dosage Form

    filter

    Lead Product

    filter

    Target

    refresh Filters
    refresh Reset Filter
    refresh Reset Filter
    price-trend All Developments

    Therapeutic Area by Lead Product

    ForexGraph

    Study Phase by Lead Product

    ForexGraph

    Company by Lead Product

    ForexGraph

    Top Deals by Deal Size (USD bn)

    ForexGraph

    01

    Pierre Fabre

    France arrow
    ICHH-25
    Not Confirmed

    Pierre Fabre

    France arrow
    ICHH-25
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Idazoxan

    Therapeutic Area : Psychiatry/Psychology

    Study Phase : Phase II

    Sponsor : Terran Biosciences

    Deal Size : Undisclosed

    Deal Type : Licensing Agreement

    DEALS_DEV arrow-down

    Terran Biosciences Announces Exclusive Licensing Deal with Pierre Fabre for Idazoxan; Terran Completes Key Dev...

    Details : Under the agreement, Terran obtains exclusive global development and commercialization rights for idazoxan hydrochloride, a selective alpha 2 receptor antagonist and a late-stage clinical therapeutic for the treatment of schizophrenia.

    Product Name : Undisclosed

    Product Type : Small molecule

    Upfront Cash : Undisclosed

    June 02, 2023

    Lead Product(s) : Idazoxan

    Therapeutic Area : Psychiatry/Psychology

    Highest Development Status : Phase II

    Sponsor : Terran Biosciences

    Deal Size : Undisclosed

    Deal Type : Licensing Agreement

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth